🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the effort against increasingly resistant strains of the infection, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing around the world, with estimates suggesting in excess of 82 million infections annually. Especially elevated rates are seen in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Clearance

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, also received approval in close succession. This medication, which is also used to treat UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a unique collaborative effort for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to see it through.

“This approval marks a huge turning point in the treatment of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Results and Worldwide Availability

As per findings published in a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This places it at an comparable level with the existing first-line therapy, which uses a dual-drug approach. The research included hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. The availability of a easy-to-administer therapy like this is seen as a "game-changer" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for patients and to prevent the spread of extremely resistant gonorrhoea globally.